Literature DB >> 23019232

Glucagon-like peptide-1 receptor stimulation increases GFR and suppresses proximal reabsorption in the rat.

Scott C Thomson1, Ali Kashkouli, Prabhleen Singh.   

Abstract

The incretin hormone glucagon-like peptide-1 (GLP-1) is released from the gut in response to fat or carbohydrate and contributes to negative feedback control of blood glucose by stimulating insulin secretion, inhibiting glucagon, and slowing gastric emptying. GLP-1 receptors (GLP-1R) are also expressed in the proximal tubule, and possibly elsewhere in the kidney. Presently, we examined the effect of a GLP-1R agonist on single-nephron glomerular filtration rate (GFR; SNGFR), proximal reabsorption (Jprox), tubuloglomerular feedback (TGF) responses, and urine flow rate in hydropenic male Wistar and Wistar-Froemter rats. Micropuncture and whole-kidney data were obtained before and during infusion of the GLP-1 agonist exenatide (1 nmol/h iv). SNGFR and Jprox were measured by late proximal collection at both extremes of TGF activation, which was achieved by perfusing Henle's loop at 0 or 50 nl/min. Primary changes in Jprox were revealed by analysis of covariance for Jprox with SNGFR as a covariate. Effects on TGF activation were determined in a separate set of experiments by comparing early distal and late proximal collections. Exenatide increased SNGFR by 33-50%, suppressed proximal tubular reabsorption by 20-40%, doubled early distal flow rate, and increased urine flow rate sixfold without altering the efficiency of glomerulotubular balance, TGF responsiveness, or the tonic influence of TGF. This implies that exenatide is both a proximal diuretic and a renal vasodilator. Since the natural agonist for the GLP-1R is regulated by intake of fat and carbohydrate, but not by salt or fluid, the control of salt excretion by the GLP-1R system departs from the usual negative-feedback paradigm for regulating salt balance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23019232      PMCID: PMC3543628          DOI: 10.1152/ajprenal.00064.2012

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  34 in total

1.  Renal effects of glucagon-like peptide in rats.

Authors:  Carol Moreno; Mahesh Mistry; Richard J Roman
Journal:  Eur J Pharmacol       Date:  2002-01-11       Impact factor: 4.432

2.  Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat.

Authors:  Scott C Thomson; Timo Rieg; Cynthia Miracle; Hadi Mansoury; Jean Whaley; Volker Vallon; Prabhleen Singh
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-09-21       Impact factor: 3.619

3.  Stable expression of the rat GLP-I receptor in CHO cells: activation and binding characteristics utilizing GLP-I(7-36)-amide, oxyntomodulin, exendin-4, and exendin(9-39).

Authors:  H C Fehmann; J Jiang; J Schweinfurth; M B Wheeler; A E Boyd; B Göke
Journal:  Peptides       Date:  1994       Impact factor: 3.750

4.  The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent.

Authors:  Brian L Furman
Journal:  Toxicon       Date:  2010-12-29       Impact factor: 3.033

5.  Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1.

Authors:  Renato O Crajoinas; Felipe T Oricchio; Thaissa D Pessoa; Bruna P M Pacheco; Lucília M A Lessa; Gerhard Malnic; Adriana C C Girardi
Journal:  Am J Physiol Renal Physiol       Date:  2011-05-18

6.  Homeostatic efficiency of tubuloglomerular feedback in hydropenia, euvolemia, and acute volume expansion.

Authors:  S C Thomson; R C Blantz
Journal:  Am J Physiol       Date:  1993-06

7.  Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats.

Authors:  Ming Yu; Carol Moreno; Kimberly M Hoagland; Annette Dahly; Katie Ditter; Mahesh Mistry; Richard J Roman
Journal:  J Hypertens       Date:  2003-06       Impact factor: 4.844

8.  Ornithine decarboxylase, kidney size, and the tubular hypothesis of glomerular hyperfiltration in experimental diabetes.

Authors:  S C Thomson; A Deng; D Bao; J Satriano; R C Blantz; V Vallon
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

9.  Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men.

Authors:  Jean-Pierre Gutzwiller; Stefan Tschopp; Andreas Bock; Carlos E Zehnder; Andreas R Huber; Monika Kreyenbuehl; Heike Gutmann; Jürgen Drewe; Christoph Henzen; Burkhard Goeke; Christoph Beglinger
Journal:  J Clin Endocrinol Metab       Date:  2004-06       Impact factor: 5.958

Review 10.  Urea transport in the kidney.

Authors:  Janet D Klein; Mitsi A Blount; Jeff M Sands
Journal:  Compr Physiol       Date:  2011-04       Impact factor: 9.090

View more
  26 in total

Review 1.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

Review 2.  Renal Effects of Incretin-Based Diabetes Therapies: Pre-clinical Predictions and Clinical Trial Outcomes.

Authors:  Scott C Thomson; Volker Vallon
Journal:  Curr Diab Rep       Date:  2018-04-13       Impact factor: 4.810

3.  The role of incretin as an integrator of sodium and water balance regulation.

Authors:  Yu V Natochin; A S Marina; A V Kutina
Journal:  Dokl Biol Sci       Date:  2014-11-05

4.  Stimulation of glucagon-like peptide-1 secretion by water loading in human.

Authors:  A S Marina; A V Kutina; E I Shakhmatova; E V Balbotkina; Yu V Natochin
Journal:  Dokl Biol Sci       Date:  2015-01-06

5.  Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials.

Authors:  Vivian A Fonseca; J Hans Devries; Robert R Henry; Morten Donsmark; Henrik F Thomsen; Jorge Plutzky
Journal:  J Diabetes Complications       Date:  2014-01-21       Impact factor: 2.852

6.  Hypoxia-inducible factor-1α activation improves renal oxygenation and mitochondrial function in early chronic kidney disease.

Authors:  Joanna L Thomas; Hai Pham; Ying Li; Elanore Hall; Guy A Perkins; Sameh S Ali; Hemal H Patel; Prabhleen Singh
Journal:  Am J Physiol Renal Physiol       Date:  2017-03-22

Review 7.  Effects of GLP-1 in the kidney.

Authors:  Jeppe Skov
Journal:  Rev Endocr Metab Disord       Date:  2014-09       Impact factor: 6.514

8.  Renal hemodynamic effects of glucagon-like peptide-1 agonist are mediated by nitric oxide but not prostaglandin.

Authors:  Scott C Thomson; Ali Kashkouli; Zhi Zhao Liu; Prabhleen Singh
Journal:  Am J Physiol Renal Physiol       Date:  2017-07-19

9.  Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection.

Authors:  Daisuke Katagiri; Yoshifumi Hamasaki; Kent Doi; Koji Okamoto; Kousuke Negishi; Masaomi Nangaku; Eisei Noiri
Journal:  J Am Soc Nephrol       Date:  2013-10-03       Impact factor: 10.121

Review 10.  Intestinal regulation of urinary sodium excretion and the pathophysiology of diabetic kidney disease: a focus on glucagon-like peptide 1 and dipeptidyl peptidase 4.

Authors:  Volker Vallon; Neil G Docherty
Journal:  Exp Physiol       Date:  2014-08-01       Impact factor: 2.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.